Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said a post hoc analysis of data from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial was published in the The Lancet. An analysis of data from the study showed that in patients with type 2 diabetes and recent acute coronary syndrome (ACS), dipeptidyl peptidase 4 inhibitor (DPP-4i) alogliptin compared to placebo did not increase the risk of heart failure (HF) outcomes. Alogliptin (n = 201, 7.4 percent) compared with placebo (n = 201, 7.5 percent) had no effect on the extended exploratory post hoc composite endpoint of CV death and hospitalized heart failure (HHF). Patients with a history of HF prior to randomization had a higher risk of HF outcomes in EXAMINE. The subanalysis showed that the risk of the composite of CV death and HHF was not increased with alogliptin (n = 107, 13.9 percent) compared with placebo (n = 120, 15.7 percent). In patients without a history of HF at baseline, there was also no increased risk of the composite endpoint of CV death and HHF for alogliptin (p = 0.337) vs. placebo, although there was in that subgroup of patients a small absolute increase in HHF for alogliptin vs. placebo (0.9 percent).